Assessment of anxiolytic activity of Mundi (Sphaeranthus indicus Linn) in patients of Generalized Anxiety Disorder.

Pharmacoinformatics and Clinical Insights: Unraveling the Therapeutic Potential of Mundi (Sphaeranthus indicus Linn) in Generalized Anxiety Disorder through In-silico Analysis and Randomized Open-Labelled Comparative Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064361

Enrollment

100

Registered

2024-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: A. Patients fulfilling the criteria of Generalized Anxiety Disorder as per DSM V guidelines. B. Hamilton anxiety score more than 17. C. Age 20 to 40 years, irrespective to gender, caste, socio-economic status etc.

Exclusion criteria

Exclusion criteria: 1. Patient suffering from any psychiatric disorder other than GAD. 2. Patient suffering from any major systemic disease requiring significant care. 3. Patient with serious suicidal & Homicidal risk, substance, or alcohol dependence. 4. Pregnant women and lactating mothers. 5. Patient not willing to participate in study.

Design outcomes

Primary

Measure	Time frame
HARS LESS THAN 17Timepoint: HARS LESS THAN 17	—

Secondary

Measure	Time frame
IMPROVEMENT IN GAD 7 SCALETimepoint: AFTER 2 MONTHS	—

Countries

India

Contacts

Public ContactDR SHIVANI GHILDIYAL

ALL INDIA INSTITUTE OF AYURVEDA

drshivanighildiyal@gmail.com8765363310

Outcome results